Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA534702
Max Phase: Preclinical
Molecular Formula: C37H42ClN3O6
Molecular Weight: 623.75
Molecule Type: Small molecule
Associated Items:
ID: ALA534702
Max Phase: Preclinical
Molecular Formula: C37H42ClN3O6
Molecular Weight: 623.75
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCOC(=O)C1C(=O)C=C(c2ccccc2)C(C)N1C.Cl.O=C(O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1
Standard InChI: InChI=1S/C21H22N2O3.C16H19NO3.ClH/c24-21(25)19-12-7-13-23(16-19)14-15-26-22-20(17-8-3-1-4-9-17)18-10-5-2-6-11-18;1-4-20-16(19)15-14(18)10-13(11(2)17(15)3)12-8-6-5-7-9-12;/h1-6,8-12H,7,13-16H2,(H,24,25);5-11,15H,4H2,1-3H3;1H
Standard InChI Key: PKILDFPWJNRFGM-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 623.75 | Molecular Weight (Monoisotopic): 623.2995 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Héja L, Kovács I, Szárics E, Incze M, Temesváriné-Major E, Dörnyei G, Peredy-Kajtár M, Gács-Baitz E, Szántay C, Kardos J.. (2004) Novel secoergoline derivatives inhibit both GABA and glutamate uptake in rat brain homogenates: synthesis, in vitro pharmacology, and modeling., 47 (23): [PMID:15509161] [10.1021/jm040809c] |
Source(1):